Evaluation of a new VIDAS® test for the detection of Epstein-Barr virus VCA IgG & IgM and EBNA IgG antibodies in human serum samples
Abstract number: P778
Allard L., Foussadier A., Desmottes P.
Objective: The aim of the study was to evaluate the performance of the 3 new automated VIDAS Epstein-Barr virus (EBV) reagents for the determination of the patient EBV serological characterised. The EBV reagents currently under development on VIDAS instrument are aimed to detect immunoglobulins against Viral Capside Antigen (VCA) and Epstein-Barr nuclear antigen (EBNA):VIDAS VCA IgG, VIDAS VCA IgM and VIDAS EBNA IgG
A comparison of the VIDAS EBV® tests was performed with EBV automated tests on the LIAISON® system (DiaSorin, Italy) using characterised sera samples.
Methods: VIDAS EBV VCA IgG and EBNA IgG reagents use specific EBV peptides coated on the solid phase to capture viral antigen immunoglobulins. The peptide-EBV IgG antibody complexes are later revealed using an anti-human IgG conjugated to Alkalin Phosphatase.
VIDAS EBV VCA IgM is based on immunocapture of serum EBV IgM.
Twenty four sera from EBV primary infection, 20 sera from EBV past infection and 31 negative sera samples with a clinical status determined with the Immunofluorescence Gold Standard method (IF) were tested with the 3 VIDAS EBV markers to determine the performance. A concordance analysis between VIDAS and LIAISON was performed on an average of 75 samples on the 3 reagents. Discrepant results were analysed using IF.
Results: On defined IF characterised samples, the specificity of VIDAS VCA IgM, VCA IgG and EBNA IgG were 96.1%, 96.4% and 100% respectively and the sensitivity of VIDAS VCA IgM, VCA IgG and EBNA IgG were 100%, 95.6% and 100% respectively. For comparison, the specificity of LIAISON VCA IgM, VCA IgG and EBNA IgG were 98.0%, 96.4% and 97.6% respectively and the sensitivity of LIAISON VCA IgM, VCA IgG and EBNA IgG were 100%, 91.1% and 100% respectively.
Therefore, on this preliminary study VIDAS EBV overall performance leads to a more accurate clinical diagnosis of EBV primary infection than LIAISON EBV.
On random samples the concordance between VIDAS and Liaison VCA IgG, VCA IgM and EBNA IgG is 97.3%, 97.3% and 98.6%, respectively.
Conclusion: The new VIDAS EBV reagents presented good performance in accordance with the patients' serological status established with the IF. Evaluation on routine samples has also shown that VIDAS EBV reagents performed better than another automated test. VIDAS EBV reagents will be a good alternative to currently used manual method for MNI determination enabling single testing as well as series.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|